For the quarter ended December 2023, Myriad Genetics (MYGN - Free Report) reported revenue of $196.6 million, up 10.6% over the same period last year. EPS came in at $0.04, compared to -$0.12 in the year-ago quarter.
The reported revenue represents a surprise of +1.17% over the Zacks Consensus Estimate of $194.33 million. With the consensus EPS estimate being $0.02, the EPS surprise was +100.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Myriad performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue by Product- Prenatal: $40 million compared to the $34.75 million average estimate based on two analysts. The reported number represents a change of +37.5% year over year.
- Revenue by Product- Hereditary Cancer: $88.90 million versus $91.09 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.
- Revenue by Product- Pharmacogenomics: $35.60 million versus $33.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.
- Revenue by Product- Tumor Profiling: $32.10 million compared to the $37.53 million average estimate based on two analysts. The reported number represents a change of +1.3% year over year.
View all Key Company Metrics for Myriad here>>>Shares of Myriad have returned +0.9% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
For the quarter ended December 2023, Myriad Genetics (MYGN - Free Report) reported revenue of $196.6 million, up 10.6% over the same period last year. EPS came in at $0.04, compared to -$0.12 in the year-ago quarter.
The reported revenue represents a surprise of +1.17% over the Zacks Consensus Estimate of $194.33 million. With the consensus EPS estimate being $0.02, the EPS surprise was +100.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Myriad performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue by Product- Prenatal: $40 million compared to the $34.75 million average estimate based on two analysts. The reported number represents a change of +37.5% year over year.
- Revenue by Product- Hereditary Cancer: $88.90 million versus $91.09 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.
- Revenue by Product- Pharmacogenomics: $35.60 million versus $33.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.
- Revenue by Product- Tumor Profiling: $32.10 million compared to the $37.53 million average estimate based on two analysts. The reported number represents a change of +1.3% year over year.
View all Key Company Metrics for Myriad here>>>Shares of Myriad have returned +0.9% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on MYGN - FREE